Prenetics’ IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

Rhea-AI Summary

Prenetics' IM8 has announced a collaboration with Mayo Clinic to develop a new line of premium supplements, focusing on nutrition, cellular rejuvenation, protein, collagen, and overall wellness. The partnership, announced after IM8's official launch on November 18th on IM8health.com, combines IM8's innovation with Mayo Clinic's medical expertise to create evidence-based, clinically researched supplements.

The collaboration includes contributions from Dr. Dawn Mussallem, a Mayo Clinic integrative oncologist who serves on IM8's Scientific Advisory Board. Mayo Clinic maintains a financial interest in the referenced technology and will direct any revenue toward its not-for-profit mission in patient care, education, and research.

Positive

• Strategic partnership with prestigious Mayo Clinic enhances product credibility
• Access to Mayo Clinic's medical expertise for product development
• Addition of Mayo Clinic integrative oncologist to Scientific Advisory Board

Negative

• None.

Insights

Healthcare Industry Analyst

The collaboration between Prenetics' IM8 and Mayo Clinic represents a strategic move in the premium supplements market. While Mayo Clinic's reputation adds significant credibility, several critical factors warrant consideration. The supplements industry faces intense competition and strict regulatory oversight, with global market projections reaching $272.4 billion by 2028. Mayo Clinic's financial stake in the technology suggests potential revenue-sharing arrangements, though specific terms remain undisclosed. Dr. Mussallem's involvement as an integrative oncologist particularly positions IM8 to potentially develop specialized supplements for cancer patients and survivors - a growing market segment. However, the success hinges heavily on clinical validation and market differentiation in an already saturated space.

Market Research Analyst

The strategic timing of this partnership, following IM8's November launch, indicates a calculated market entry strategy. Premium supplements command higher margins, typically 40-60% compared to 20-30% for standard supplements. Mayo Clinic's brand association could justify premium pricing and accelerate market penetration, particularly among health-conscious consumers willing to pay more for clinically-validated products. The focus on cellular rejuvenation and collagen health aligns with current wellness trends and aging population demands. The collaboration's emphasis on scientific rigor addresses growing consumer skepticism in the supplement industry, where only 24% of consumers fully trust supplement claims. This partnership could significantly enhance Prenetics' market position and revenue potential.

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness

IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics’ (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to develop a new generation of premium supplements. This collaboration aims to advance health and longevity through the fusion of IM8’s cutting-edge innovation and Mayo Clinic’s medical expertise.

The collaboration will focus on creating evidence-based, clinically researched supplements designed to address key health priorities such as optimal nutrition, cellular rejuvenation, protein support, collagen health, muscle recovery, and overall well-being. The work seeks to ensure that every product developed meets the highest standards of science and efficacy, empowering individuals to take charge of their health with confidence.

“This collaboration with Mayo Clinic marks a significant milestone for IM8,” said Danny Yeung, CEO of Prenetics. “Together, we aim to redefine health and wellness by creating premium supplements that merge scientific rigor with tangible health benefits. Our work has already started, and the initial research is yielding highly promising insights that inspire confidence in the potential of this initiative.”

The collaboration includes contributions from Dawn Mussallem, M.D., a Mayo Clinic integrative oncologist and a member of IM8’s Scientific Advisory Board. Dr. Mussallem’s unique medical insights will guide the development of supplements that address key health priorities with precision and scientific rigor.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

ABOUT PRENETICS
Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand, and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our $200 million venture focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for comprehensive genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer comprehensive DNA tests. Each of Prenetics’ units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science’. To learn more about Prenetics, please visit prenetics.com.

Investor Relations Contact:

Angela Cheung
Investor Relations / Corporate Finance
Prenetics Global Limited
angela.hm.cheung@prenetics.com

Shannon Devine
MZ North America
Main: 203-741-8811
shannon.devine@mzgroup.us

FAQ

What is the focus of Prenetics' IM8 and Mayo Clinic collaboration?

The collaboration focuses on developing premium supplements targeting nutrition, cellular rejuvenation, protein support, collagen health, muscle recovery, and overall wellness through evidence-based research.

When did Prenetics (PRE) launch the IM8 supplement brand?

IM8 was officially launched on November 18th, 2023, through their website IM8health.com.

How will Mayo Clinic benefit from the collaboration with Prenetics' IM8?

Mayo Clinic has a financial interest in the technology and will use any revenue received to support its not-for-profit mission in patient care, education, and research.

Who is involved in the scientific development of IM8's supplements?

Dr. Dawn Mussallem, a Mayo Clinic integrative oncologist, serves on IM8's Scientific Advisory Board and contributes to the supplement development process.